#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Engineered proteins with tailored properties evolved from natural precursors have been playing an increasingly important role in a spectrum of agricultural , industrial , and biomedical applications .
3-1	17-27	Engineered	substance[3]	new[3]	coref	8-18[0_3]
3-2	28-36	proteins	substance[3]	new[3]	_	_
3-3	37-41	with	substance[3]	new[3]	_	_
3-4	42-50	tailored	substance[3]|abstract[4]	new[3]|new[4]	coref	22-5[161_4]
3-5	51-61	properties	substance[3]|abstract[4]	new[3]|new[4]	_	_
3-6	62-69	evolved	_	_	_	_
3-7	70-74	from	_	_	_	_
3-8	75-82	natural	substance[5]	new[5]	_	_
3-9	83-93	precursors	substance[5]	new[5]	_	_
3-10	94-98	have	_	_	_	_
3-11	99-103	been	_	_	_	_
3-12	104-111	playing	_	_	_	_
3-13	112-114	an	abstract[6]	new[6]	coref	6-7[38_6]
3-14	115-127	increasingly	abstract[6]	new[6]	_	_
3-15	128-137	important	abstract[6]	new[6]	_	_
3-16	138-142	role	abstract[6]	new[6]	_	_
3-17	143-145	in	_	_	_	_
3-18	146-147	a	abstract[7]	new[7]	_	_
3-19	148-156	spectrum	abstract[7]	new[7]	_	_
3-20	157-159	of	abstract[7]	new[7]	_	_
3-21	160-172	agricultural	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-22	173-174	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-23	175-185	industrial	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-24	186-187	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-25	188-191	and	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-26	192-202	biomedical	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-27	203-215	applications	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-28	216-217	.	_	_	_	_

#Text=For example , protein engineering holds the potential of transforming the metabolic drug landscape through the development of smart , stimulus-responsive drug systems .
4-1	218-221	For	_	_	_	_
4-2	222-229	example	_	_	_	_
4-3	230-231	,	_	_	_	_
4-4	232-239	protein	substance|abstract[10]	new|new[10]	coref|coref|coref|coref	5-5|5-5[19_10]|5-5|5-5[19_10]
4-5	240-251	engineering	abstract[10]	new[10]	_	_
4-6	252-257	holds	_	_	_	_
4-7	258-261	the	abstract[11]	new[11]	_	_
4-8	262-271	potential	abstract[11]	new[11]	_	_
4-9	272-274	of	_	_	_	_
4-10	275-287	transforming	_	_	_	_
4-11	288-291	the	abstract[13]	new[13]	_	_
4-12	292-301	metabolic	abstract[13]	new[13]	_	_
4-13	302-306	drug	substance|abstract[13]	new|new[13]	coref	4-22
4-14	307-316	landscape	abstract[13]	new[13]	_	_
4-15	317-324	through	_	_	_	_
4-16	325-328	the	event[14]	new[14]	_	_
4-17	329-340	development	event[14]	new[14]	_	_
4-18	341-343	of	event[14]	new[14]	_	_
4-19	344-349	smart	event[14]|abstract[16]	new[14]|new[16]	coref	13-11[93_16]
4-20	350-351	,	event[14]|abstract[16]	new[14]|new[16]	_	_
4-21	352-371	stimulus-responsive	event[14]|abstract[16]	new[14]|new[16]	_	_
4-22	372-376	drug	event[14]|substance|abstract[16]	new[14]|giv|new[16]	_	_
4-23	377-384	systems	event[14]|abstract[16]	new[14]|new[16]	_	_
4-24	385-386	.	_	_	_	_

#Text=In industrial processes , protein engineering enables the production of enzymes that offer unique advantages compared with chemical catalysts , such as biodegradability , stereoselectivity , substrate specificity , functionality under relatively mild solvents , temperatures , pHs and pressures , and stability at extreme conditions .
5-1	387-389	In	_	_	_	_
5-2	390-400	industrial	abstract[17]	new[17]	_	_
5-3	401-410	processes	abstract[17]	new[17]	_	_
5-4	411-412	,	_	_	_	_
5-5	413-420	protein	substance|abstract[19]	giv|giv[19]	coref|coref|coref|coref	6-3|6-3[37_19]|6-3|6-3[37_19]
5-6	421-432	engineering	abstract[19]	giv[19]	_	_
5-7	433-440	enables	_	_	_	_
5-8	441-444	the	event[20]	new[20]	_	_
5-9	445-455	production	event[20]	new[20]	_	_
5-10	456-458	of	event[20]	new[20]	_	_
5-11	459-466	enzymes	event[20]|substance	new[20]|new	coref	6-21[42_0]
5-12	467-471	that	_	_	_	_
5-13	472-477	offer	_	_	_	_
5-14	478-484	unique	abstract[22]	new[22]	_	_
5-15	485-495	advantages	abstract[22]	new[22]	_	_
5-16	496-504	compared	_	_	_	_
5-17	505-509	with	_	_	_	_
5-18	510-518	chemical	substance[23]	new[23]	_	_
5-19	519-528	catalysts	substance[23]	new[23]	_	_
5-20	529-530	,	substance[23]	new[23]	_	_
5-21	531-535	such	substance[23]	new[23]	_	_
5-22	536-538	as	substance[23]	new[23]	_	_
5-23	539-555	biodegradability	substance[23]|abstract	new[23]|new	_	_
5-24	556-557	,	substance[23]	new[23]	_	_
5-25	558-575	stereoselectivity	substance[23]|abstract	new[23]|new	_	_
5-26	576-577	,	substance[23]	new[23]	_	_
5-27	578-587	substrate	substance[23]|person|abstract[27]	new[23]|new|new[27]	_	_
5-28	588-599	specificity	substance[23]|abstract[27]	new[23]|new[27]	_	_
5-29	600-601	,	substance[23]	new[23]	_	_
5-30	602-615	functionality	substance[23]|abstract[28]	new[23]|new[28]	coref	20-24[147_28]
5-31	616-621	under	substance[23]|abstract[28]	new[23]|new[28]	_	_
5-32	622-632	relatively	substance[23]|abstract[28]|substance[29]	new[23]|new[28]|new[29]	_	_
5-33	633-637	mild	substance[23]|abstract[28]|substance[29]	new[23]|new[28]|new[29]	_	_
5-34	638-646	solvents	substance[23]|abstract[28]|substance[29]	new[23]|new[28]|new[29]	_	_
5-35	647-648	,	substance[23]|abstract[28]	new[23]|new[28]	_	_
5-36	649-661	temperatures	substance[23]|abstract[28]|substance	new[23]|new[28]|new	_	_
5-37	662-663	,	substance[23]|abstract[28]	new[23]|new[28]	_	_
5-38	664-667	pHs	substance[23]|abstract[28]|abstract	new[23]|new[28]|new	_	_
5-39	668-671	and	substance[23]|abstract[28]	new[23]|new[28]	_	_
5-40	672-681	pressures	substance[23]|abstract[28]|abstract	new[23]|new[28]|new	_	_
5-41	682-683	,	substance[23]	new[23]	_	_
5-42	684-687	and	substance[23]	new[23]	_	_
5-43	688-697	stability	substance[23]|abstract[33]	new[23]|new[33]	coref	22-12[0_33]
5-44	698-700	at	substance[23]|abstract[33]	new[23]|new[33]	_	_
5-45	701-708	extreme	substance[23]|abstract[33]|abstract[34]	new[23]|new[33]|new[34]	coref	20-20[0_34]
5-46	709-719	conditions	substance[23]|abstract[33]|abstract[34]	new[23]|new[33]|new[34]	_	_
5-47	720-721	.	_	_	_	_

#Text=Today , protein engineering also plays a critical role in advancing the emerging field of synthetic biology , including optimizing pathway enzymes and regulatory elements , balancing pathway redox equivalents , as well as tuning the expression of pathway genes .
6-1	722-727	Today	time	new	_	_
6-2	728-729	,	_	_	_	_
6-3	730-737	protein	substance|abstract[37]	giv|giv[37]	coref|coref|coref|coref	7-7|7-7[52_37]|7-7|7-7[52_37]
6-4	738-749	engineering	abstract[37]	giv[37]	_	_
6-5	750-754	also	_	_	_	_
6-6	755-760	plays	_	_	_	_
6-7	761-762	a	abstract[38]	giv[38]	_	_
6-8	763-771	critical	abstract[38]	giv[38]	_	_
6-9	772-776	role	abstract[38]	giv[38]	_	_
6-10	777-779	in	_	_	_	_
6-11	780-789	advancing	_	_	_	_
6-12	790-793	the	abstract[39]	new[39]	_	_
6-13	794-802	emerging	abstract[39]	new[39]	_	_
6-14	803-808	field	abstract[39]	new[39]	_	_
6-15	809-811	of	abstract[39]	new[39]	_	_
6-16	812-821	synthetic	abstract[39]|abstract[40]	new[39]|new[40]	_	_
6-17	822-829	biology	abstract[39]|abstract[40]	new[39]|new[40]	_	_
6-18	830-831	,	_	_	_	_
6-19	832-841	including	_	_	_	_
6-20	842-852	optimizing	_	_	_	_
6-21	853-860	pathway	place|substance[42]	new|giv[42]	coref|coref|coref|coref	6-28|10-39[0_42]|6-28|10-39[0_42]
6-22	861-868	enzymes	substance[42]	giv[42]	_	_
6-23	869-872	and	substance[42]	giv[42]	_	_
6-24	873-883	regulatory	substance[42]|abstract[43]	giv[42]|new[43]	coref	10-25[73_43]
6-25	884-892	elements	substance[42]|abstract[43]	giv[42]|new[43]	_	_
6-26	893-894	,	_	_	_	_
6-27	895-904	balancing	_	_	_	_
6-28	905-912	pathway	place|abstract[46]	giv|new[46]	coref|coref	6-39|6-39
6-29	913-918	redox	object|abstract[46]	new|new[46]	_	_
6-30	919-930	equivalents	abstract[46]	new[46]	_	_
6-31	931-932	,	_	_	_	_
6-32	933-935	as	_	_	_	_
6-33	936-940	well	_	_	_	_
6-34	941-943	as	_	_	_	_
6-35	944-950	tuning	_	_	_	_
6-36	951-954	the	abstract[47]	new[47]	_	_
6-37	955-965	expression	abstract[47]	new[47]	_	_
6-38	966-968	of	abstract[47]	new[47]	_	_
6-39	969-976	pathway	abstract[47]|place|abstract[49]	new[47]|giv|new[49]	_	_
6-40	977-982	genes	abstract[47]|abstract[49]	new[47]|new[49]	_	_
6-41	983-984	.	_	_	_	_

#Text=There are two main strategies in protein engineering : rational design and directed evolution .
7-1	985-990	There	_	_	_	_
7-2	991-994	are	_	_	_	_
7-3	995-998	two	abstract[50]	new[50]	appos	7-10[53_50]
7-4	999-1003	main	abstract[50]	new[50]	_	_
7-5	1004-1014	strategies	abstract[50]	new[50]	_	_
7-6	1015-1017	in	abstract[50]	new[50]	_	_
7-7	1018-1025	protein	abstract[50]|substance|abstract[52]	new[50]|giv|giv[52]	coref|coref	9-8[60_0]|9-8[60_0]
7-8	1026-1037	engineering	abstract[50]|abstract[52]	new[50]|giv[52]	_	_
7-9	1038-1039	:	_	_	_	_
7-10	1040-1048	rational	abstract[53]	giv[53]	coref	8-1[54_53]
7-11	1049-1055	design	abstract[53]	giv[53]	_	_
7-12	1056-1059	and	abstract[53]	giv[53]	_	_
7-13	1060-1068	directed	abstract[53]	giv[53]	_	_
7-14	1069-1078	evolution	abstract[53]	giv[53]	_	_
7-15	1079-1080	.	_	_	_	_

#Text=Rational design , which is mostly carried out in silico , is knowledge-based , deterministic engineering of proteins .
8-1	1081-1089	Rational	abstract[54]	giv[54]	coref	8-13[56_54]
8-2	1090-1096	design	abstract[54]	giv[54]	_	_
8-3	1097-1098	,	_	_	_	_
8-4	1099-1104	which	_	_	_	_
8-5	1105-1107	is	_	_	_	_
8-6	1108-1114	mostly	_	_	_	_
8-7	1115-1122	carried	_	_	_	_
8-8	1123-1126	out	_	_	_	_
8-9	1127-1129	in	_	_	_	_
8-10	1130-1136	silico	substance	new	_	_
8-11	1137-1138	,	_	_	_	_
8-12	1139-1141	is	_	_	_	_
8-13	1142-1157	knowledge-based	abstract[56]	giv[56]	ana	9-3[0_56]
8-14	1158-1159	,	abstract[56]	giv[56]	_	_
8-15	1160-1173	deterministic	abstract[56]	giv[56]	_	_
8-16	1174-1185	engineering	abstract[56]	giv[56]	_	_
8-17	1186-1188	of	abstract[56]	giv[56]	_	_
8-18	1189-1197	proteins	abstract[56]|substance	giv[56]|giv	coref	16-20[123_0]
8-19	1198-1199	.	_	_	_	_

#Text=Thus , it needs prior information on the target protein such as a structural model , sequence relationship to homologs , and insights into its biophysical function .
9-1	1200-1204	Thus	_	_	_	_
9-2	1205-1206	,	_	_	_	_
9-3	1207-1209	it	abstract	giv	coref	10-13[70_0]
9-4	1210-1215	needs	_	_	_	_
9-5	1216-1221	prior	_	_	_	_
9-6	1222-1233	information	abstract[59]	new[59]	coref	29-55[244_59]
9-7	1234-1236	on	abstract[59]	new[59]	_	_
9-8	1237-1240	the	abstract[59]|substance[60]	new[59]|giv[60]	coref	10-10[0_60]
9-9	1241-1247	target	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-10	1248-1255	protein	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-11	1256-1260	such	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-12	1261-1263	as	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-13	1264-1265	a	abstract[59]|substance[60]|abstract[61]	new[59]|giv[60]|new[61]	_	_
9-14	1266-1276	structural	abstract[59]|substance[60]|abstract[61]	new[59]|giv[60]|new[61]	_	_
9-15	1277-1282	model	abstract[59]|substance[60]|abstract[61]	new[59]|giv[60]|new[61]	_	_
9-16	1283-1284	,	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-17	1285-1293	sequence	abstract[59]|substance[60]|abstract|abstract[63]	new[59]|giv[60]|new|new[63]	_	_
9-18	1294-1306	relationship	abstract[59]|substance[60]|abstract[63]	new[59]|giv[60]|new[63]	_	_
9-19	1307-1309	to	abstract[59]|substance[60]|abstract[63]	new[59]|giv[60]|new[63]	_	_
9-20	1310-1318	homologs	abstract[59]|substance[60]|abstract[63]|abstract	new[59]|giv[60]|new[63]|new	_	_
9-21	1319-1320	,	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-22	1321-1324	and	abstract[59]|substance[60]	new[59]|giv[60]	_	_
9-23	1325-1333	insights	abstract[59]|substance[60]|abstract[65]	new[59]|giv[60]|new[65]	_	_
9-24	1334-1338	into	abstract[59]|substance[60]|abstract[65]	new[59]|giv[60]|new[65]	_	_
9-25	1339-1342	its	abstract[59]|substance[60]|abstract[65]|abstract[66]	new[59]|giv[60]|new[65]|new[66]	_	_
9-26	1343-1354	biophysical	abstract[59]|substance[60]|abstract[65]|abstract[66]	new[59]|giv[60]|new[65]|new[66]	_	_
9-27	1355-1363	function	abstract[59]|substance[60]|abstract[65]|abstract[66]	new[59]|giv[60]|new[65]|new[66]	_	_
9-28	1364-1365	.	_	_	_	_

#Text=As a powerful approach to test general theories in protein chemistry , rational design can be achieved either by single-point mutation , exchange of elements of secondary structure , exchange of whole domains , or by fusion of enzymes .
10-1	1366-1368	As	_	_	_	_
10-2	1369-1370	a	_	_	_	_
10-3	1371-1379	powerful	_	_	_	_
10-4	1380-1388	approach	_	_	_	_
10-5	1389-1391	to	_	_	_	_
10-6	1392-1396	test	_	_	_	_
10-7	1397-1404	general	abstract[67]	new[67]	_	_
10-8	1405-1413	theories	abstract[67]	new[67]	_	_
10-9	1414-1416	in	abstract[67]	new[67]	_	_
10-10	1417-1424	protein	abstract[67]|substance|abstract[69]	new[67]|giv|new[69]	coref|coref	13-32|13-32
10-11	1425-1434	chemistry	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-12	1435-1436	,	_	_	_	_
10-13	1437-1445	rational	abstract[70]	giv[70]	coref	12-11[87_70]
10-14	1446-1452	design	abstract[70]	giv[70]	_	_
10-15	1453-1456	can	_	_	_	_
10-16	1457-1459	be	_	_	_	_
10-17	1460-1468	achieved	_	_	_	_
10-18	1469-1475	either	abstract[71]	new[71]	coref	14-19[106_71]
10-19	1476-1478	by	abstract[71]	new[71]	_	_
10-20	1479-1491	single-point	abstract[71]	new[71]	_	_
10-21	1492-1500	mutation	abstract[71]	new[71]	_	_
10-22	1501-1502	,	_	_	_	_
10-23	1503-1511	exchange	abstract[72]	new[72]	_	_
10-24	1512-1514	of	abstract[72]	new[72]	_	_
10-25	1515-1523	elements	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-26	1524-1526	of	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-27	1527-1536	secondary	abstract[72]|abstract[73]|abstract[74]	new[72]|giv[73]|new[74]	coref	17-13[131_74]
10-28	1537-1546	structure	abstract[72]|abstract[73]|abstract[74]	new[72]|giv[73]|new[74]	_	_
10-29	1547-1548	,	_	_	_	_
10-30	1549-1557	exchange	event[75]	new[75]	_	_
10-31	1558-1560	of	event[75]	new[75]	_	_
10-32	1561-1566	whole	event[75]|abstract[76]	new[75]|new[76]	_	_
10-33	1567-1574	domains	event[75]|abstract[76]	new[75]|new[76]	_	_
10-34	1575-1576	,	_	_	_	_
10-35	1577-1579	or	_	_	_	_
10-36	1580-1582	by	_	_	_	_
10-37	1583-1589	fusion	event[77]	new[77]	_	_
10-38	1590-1592	of	event[77]	new[77]	_	_
10-39	1593-1600	enzymes	event[77]|substance	new[77]|giv	coref	25-12[185_0]
10-40	1601-1602	.	_	_	_	_

#Text=Novel computational tools have constantly improved , resulting in dramatic increase in the sizes of mutant libraries that can be designed .
11-1	1603-1608	Novel	_	_	_	_
11-2	1609-1622	computational	object[79]	new[79]	_	_
11-3	1623-1628	tools	object[79]	new[79]	_	_
11-4	1629-1633	have	_	_	_	_
11-5	1634-1644	constantly	_	_	_	_
11-6	1645-1653	improved	_	_	_	_
11-7	1654-1655	,	_	_	_	_
11-8	1656-1665	resulting	_	_	_	_
11-9	1666-1668	in	_	_	_	_
11-10	1669-1677	dramatic	abstract[80]	new[80]	_	_
11-11	1678-1686	increase	abstract[80]	new[80]	_	_
11-12	1687-1689	in	abstract[80]	new[80]	_	_
11-13	1690-1693	the	abstract[80]|quantity[81]	new[80]|new[81]	_	_
11-14	1694-1699	sizes	abstract[80]|quantity[81]	new[80]|new[81]	_	_
11-15	1700-1702	of	abstract[80]|quantity[81]	new[80]|new[81]	_	_
11-16	1703-1709	mutant	abstract[80]|quantity[81]|object[82]	new[80]|new[81]|new[82]	coref	20-11[144_82]
11-17	1710-1719	libraries	abstract[80]|quantity[81]|object[82]	new[80]|new[81]|new[82]	_	_
11-18	1720-1724	that	_	_	_	_
11-19	1725-1728	can	_	_	_	_
11-20	1729-1731	be	_	_	_	_
11-21	1732-1740	designed	_	_	_	_
11-22	1741-1742	.	_	_	_	_

#Text=Genome-scale metabolic models ( GEMs ) have informed and expanded variant design for many industrially relevant microorganisms .
12-1	1743-1755	Genome-scale	abstract[84]	new[84]	appos	12-5[0_84]
12-2	1756-1765	metabolic	person|abstract[84]	new|new[84]	_	_
12-3	1766-1772	models	abstract[84]	new[84]	_	_
12-4	1773-1774	(	_	_	_	_
12-5	1775-1779	GEMs	abstract	giv	_	_
12-6	1780-1781	)	_	_	_	_
12-7	1782-1786	have	_	_	_	_
12-8	1787-1795	informed	_	_	_	_
12-9	1796-1799	and	_	_	_	_
12-10	1800-1808	expanded	_	_	_	_
12-11	1809-1816	variant	object|abstract[87]	new|giv[87]	coref|coref|coref|coref	15-16[114_87]|26-27[202_0]|15-16[114_87]|26-27[202_0]
12-12	1817-1823	design	abstract[87]	giv[87]	_	_
12-13	1824-1827	for	abstract[87]	giv[87]	_	_
12-14	1828-1832	many	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
12-15	1833-1845	industrially	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
12-16	1846-1854	relevant	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
12-17	1855-1869	microorganisms	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
12-18	1870-1871	.	_	_	_	_

#Text=Furthermore , multiplex automated genome evolution ( MAGE ) and CRISPR/Cas systems have significantly improved the throughput of genome editing with precision and reduced cost and time required to explore many protein targets .
13-1	1872-1883	Furthermore	_	_	_	_
13-2	1884-1885	,	_	_	_	_
13-3	1886-1895	multiplex	abstract[90]	new[90]	appos	13-8[0_90]
13-4	1896-1905	automated	abstract[90]	new[90]	_	_
13-5	1906-1912	genome	abstract|abstract[90]	new|new[90]	coref	13-19
13-6	1913-1922	evolution	abstract[90]	new[90]	_	_
13-7	1923-1924	(	_	_	_	_
13-8	1925-1929	MAGE	abstract	giv	coref	14-4
13-9	1930-1931	)	_	_	_	_
13-10	1932-1935	and	_	_	_	_
13-11	1936-1946	CRISPR/Cas	organization|abstract[93]	new|giv[93]	coref|coref	19-13[142_93]|19-13[142_93]
13-12	1947-1954	systems	abstract[93]	giv[93]	_	_
13-13	1955-1959	have	_	_	_	_
13-14	1960-1973	significantly	_	_	_	_
13-15	1974-1982	improved	_	_	_	_
13-16	1983-1986	the	abstract[94]	new[94]	_	_
13-17	1987-1997	throughput	abstract[94]	new[94]	_	_
13-18	1998-2000	of	abstract[94]	new[94]	_	_
13-19	2001-2007	genome	abstract[94]|abstract	new[94]|giv	_	_
13-20	2008-2015	editing	_	_	_	_
13-21	2016-2020	with	_	_	_	_
13-22	2021-2030	precision	abstract	new	_	_
13-23	2031-2034	and	_	_	_	_
13-24	2035-2042	reduced	abstract[97]	new[97]	_	_
13-25	2043-2047	cost	abstract[97]	new[97]	_	_
13-26	2048-2051	and	_	_	_	_
13-27	2052-2056	time	time	new	_	_
13-28	2057-2065	required	_	_	_	_
13-29	2066-2068	to	_	_	_	_
13-30	2069-2076	explore	_	_	_	_
13-31	2077-2081	many	abstract[100]	new[100]	coref	14-23[109_100]
13-32	2082-2089	protein	substance|abstract[100]	giv|new[100]	coref	15-17
13-33	2090-2097	targets	abstract[100]	new[100]	_	_
13-34	2098-2099	.	_	_	_	_

#Text=For example , MAGE enables the rapid generation of billions of mutants by repeated insertion , deletion or mutation of DNA at multiple chromosomal targets .
14-1	2100-2103	For	_	_	_	_
14-2	2104-2111	example	_	_	_	_
14-3	2112-2113	,	_	_	_	_
14-4	2114-2118	MAGE	abstract	giv	coref	16-1[119_0]
14-5	2119-2126	enables	_	_	_	_
14-6	2127-2130	the	abstract[102]	new[102]	_	_
14-7	2131-2136	rapid	abstract[102]	new[102]	_	_
14-8	2137-2147	generation	abstract[102]	new[102]	_	_
14-9	2148-2150	of	abstract[102]	new[102]	_	_
14-10	2151-2159	billions	abstract[102]|quantity[103]	new[102]|new[103]	coref	20-15[0_103]
14-11	2160-2162	of	abstract[102]|quantity[103]	new[102]|new[103]	_	_
14-12	2163-2170	mutants	abstract[102]|quantity[103]	new[102]|new[103]	_	_
14-13	2171-2173	by	_	_	_	_
14-14	2174-2182	repeated	event[104]	new[104]	_	_
14-15	2183-2192	insertion	event[104]	new[104]	_	_
14-16	2193-2194	,	_	_	_	_
14-17	2195-2203	deletion	event	new	_	_
14-18	2204-2206	or	_	_	_	_
14-19	2207-2215	mutation	abstract[106]	giv[106]	_	_
14-20	2216-2218	of	abstract[106]	giv[106]	_	_
14-21	2219-2222	DNA	abstract[106]|substance[107]	giv[106]|new[107]	_	_
14-22	2223-2225	at	abstract[106]|substance[107]	giv[106]|new[107]	_	_
14-23	2226-2234	multiple	abstract[106]|substance[107]|abstract[109]	giv[106]|new[107]|giv[109]	_	_
14-24	2235-2246	chromosomal	abstract[106]|substance[107]|animal|abstract[109]	giv[106]|new[107]|new|giv[109]	_	_
14-25	2247-2254	targets	abstract[106]|substance[107]|abstract[109]	giv[106]|new[107]|giv[109]	_	_
14-26	2255-2256	.	_	_	_	_

#Text=Overall , the unprecedented capability of designing and building a large number of variants for rational protein design has placed increased demands on the throughput of screening and selection .
15-1	2257-2264	Overall	_	_	_	_
15-2	2265-2266	,	_	_	_	_
15-3	2267-2270	the	abstract[110]	new[110]	_	_
15-4	2271-2284	unprecedented	abstract[110]	new[110]	_	_
15-5	2285-2295	capability	abstract[110]	new[110]	_	_
15-6	2296-2298	of	_	_	_	_
15-7	2299-2308	designing	_	_	_	_
15-8	2309-2312	and	_	_	_	_
15-9	2313-2321	building	_	_	_	_
15-10	2322-2323	a	abstract[111]	new[111]	_	_
15-11	2324-2329	large	abstract[111]	new[111]	_	_
15-12	2330-2336	number	abstract[111]	new[111]	_	_
15-13	2337-2339	of	abstract[111]	new[111]	_	_
15-14	2340-2348	variants	abstract[111]|object[112]	new[111]|new[112]	coref	21-8[150_112]
15-15	2349-2352	for	abstract[111]|object[112]	new[111]|new[112]	_	_
15-16	2353-2361	rational	abstract[111]|object[112]|abstract[114]	new[111]|new[112]|giv[114]	coref	17-2[127_114]
15-17	2362-2369	protein	abstract[111]|object[112]|substance|abstract[114]	new[111]|new[112]|giv|giv[114]	coref	17-3
15-18	2370-2376	design	abstract[111]|object[112]|abstract[114]	new[111]|new[112]|giv[114]	_	_
15-19	2377-2380	has	_	_	_	_
15-20	2381-2387	placed	_	_	_	_
15-21	2388-2397	increased	abstract[115]	new[115]	_	_
15-22	2398-2405	demands	abstract[115]	new[115]	_	_
15-23	2406-2408	on	abstract[115]	new[115]	_	_
15-24	2409-2412	the	abstract[115]|abstract[116]	new[115]|new[116]	_	_
15-25	2413-2423	throughput	abstract[115]|abstract[116]	new[115]|new[116]	_	_
15-26	2424-2426	of	abstract[115]|abstract[116]	new[115]|new[116]	_	_
15-27	2427-2436	screening	abstract[115]|abstract[116]|abstract	new[115]|new[116]|new	coref	21-6[149_0]
15-28	2437-2440	and	abstract[115]|abstract[116]	new[115]|new[116]	_	_
15-29	2441-2450	selection	abstract[115]|abstract[116]|abstract	new[115]|new[116]|new	coref	16-13[121_0]
15-30	2451-2452	.	_	_	_	_

#Text=Directed evolution , on the other hand , mimics the process of natural selection through random mutagenesis to steer proteins or nucleic acids toward desired traits .
16-1	2453-2461	Directed	abstract[119]	giv[119]	coref	17-6[128_119]
16-2	2462-2471	evolution	abstract[119]	giv[119]	_	_
16-3	2472-2473	,	abstract[119]	giv[119]	_	_
16-4	2474-2476	on	abstract[119]	giv[119]	_	_
16-5	2477-2480	the	abstract[119]	giv[119]	_	_
16-6	2481-2486	other	abstract[119]	giv[119]	_	_
16-7	2487-2491	hand	abstract[119]	giv[119]	_	_
16-8	2492-2493	,	_	_	_	_
16-9	2494-2500	mimics	_	_	_	_
16-10	2501-2504	the	abstract[120]	new[120]	_	_
16-11	2505-2512	process	abstract[120]	new[120]	_	_
16-12	2513-2515	of	abstract[120]	new[120]	_	_
16-13	2516-2523	natural	abstract[120]|abstract[121]	new[120]|giv[121]	coref	25-9[184_121]
16-14	2524-2533	selection	abstract[120]|abstract[121]	new[120]|giv[121]	_	_
16-15	2534-2541	through	abstract[120]|abstract[121]	new[120]|giv[121]	_	_
16-16	2542-2548	random	abstract[120]|abstract[121]|event[122]	new[120]|giv[121]|new[122]	_	_
16-17	2549-2560	mutagenesis	abstract[120]|abstract[121]|event[122]	new[120]|giv[121]|new[122]	_	_
16-18	2561-2563	to	_	_	_	_
16-19	2564-2569	steer	_	_	_	_
16-20	2570-2578	proteins	substance[123]	giv[123]	coref	22-1[0_123]
16-21	2579-2581	or	substance[123]	giv[123]	_	_
16-22	2582-2589	nucleic	substance[123]|substance[124]	giv[123]|new[124]	_	_
16-23	2590-2595	acids	substance[123]|substance[124]	giv[123]|new[124]	_	_
16-24	2596-2602	toward	_	_	_	_
16-25	2603-2610	desired	abstract[125]	new[125]	coref	21-10[151_125]
16-26	2611-2617	traits	abstract[125]	new[125]	_	_
16-27	2618-2619	.	_	_	_	_

#Text=Unlike rational protein design , directed evolution requires neither prior knowledge of a protein ’s detailed structure nor prediction of the effects of various mutations .
17-1	2620-2626	Unlike	_	_	_	_
17-2	2627-2635	rational	abstract[127]	giv[127]	_	_
17-3	2636-2643	protein	substance|abstract[127]	giv|giv[127]	coref	17-14[130_0]
17-4	2644-2650	design	abstract[127]	giv[127]	_	_
17-5	2651-2652	,	_	_	_	_
17-6	2653-2661	directed	abstract[128]	giv[128]	coref	18-3[135_128]
17-7	2662-2671	evolution	abstract[128]	giv[128]	_	_
17-8	2672-2680	requires	_	_	_	_
17-9	2681-2688	neither	_	_	_	_
17-10	2689-2694	prior	_	_	_	_
17-11	2695-2704	knowledge	abstract[129]	new[129]	ana	18-6[0_129]
17-12	2705-2707	of	abstract[129]	new[129]	_	_
17-13	2708-2709	a	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
17-14	2710-2717	protein	abstract[129]|substance[130]|abstract[131]	new[129]|giv[130]|giv[131]	coref	18-11[0_130]
17-15	2718-2720	’s	abstract[129]|substance[130]|abstract[131]	new[129]|giv[130]|giv[131]	_	_
17-16	2721-2729	detailed	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
17-17	2730-2739	structure	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
17-18	2740-2743	nor	abstract[129]	new[129]	_	_
17-19	2744-2754	prediction	abstract[129]|abstract[132]	new[129]|new[132]	_	_
17-20	2755-2757	of	abstract[129]|abstract[132]	new[129]|new[132]	_	_
17-21	2758-2761	the	abstract[129]|abstract[132]|abstract[133]	new[129]|new[132]|new[133]	_	_
17-22	2762-2769	effects	abstract[129]|abstract[132]|abstract[133]	new[129]|new[132]|new[133]	_	_
17-23	2770-2772	of	abstract[129]|abstract[132]|abstract[133]	new[129]|new[132]|new[133]	_	_
17-24	2773-2780	various	abstract[129]|abstract[132]|abstract[133]|abstract[134]	new[129]|new[132]|new[133]|new[134]	_	_
17-25	2781-2790	mutations	abstract[129]|abstract[132]|abstract[133]|abstract[134]	new[129]|new[132]|new[133]|new[134]	_	_
17-26	2791-2792	.	_	_	_	_

#Text=Indeed , directed evolution makes it possible to identify undiscovered protein sequences which have novel functions .
18-1	2793-2799	Indeed	_	_	_	_
18-2	2800-2801	,	_	_	_	_
18-3	2802-2810	directed	abstract[135]	giv[135]	coref	19-9[141_135]
18-4	2811-2820	evolution	abstract[135]	giv[135]	_	_
18-5	2821-2826	makes	_	_	_	_
18-6	2827-2829	it	abstract	giv	_	_
18-7	2830-2838	possible	_	_	_	_
18-8	2839-2841	to	_	_	_	_
18-9	2842-2850	identify	_	_	_	_
18-10	2851-2863	undiscovered	abstract[138]	new[138]	_	_
18-11	2864-2871	protein	substance|abstract[138]	giv|new[138]	coref	23-15
18-12	2872-2881	sequences	abstract[138]	new[138]	_	_
18-13	2882-2887	which	_	_	_	_
18-14	2888-2892	have	_	_	_	_
18-15	2893-2898	novel	abstract[139]	new[139]	_	_
18-16	2899-2908	functions	abstract[139]	new[139]	_	_
18-17	2909-2910	.	_	_	_	_

#Text=Moreover , synthetic biologists also increasingly rely on directed evolution to optimize engineered biological systems .
19-1	2911-2919	Moreover	_	_	_	_
19-2	2920-2921	,	_	_	_	_
19-3	2922-2931	synthetic	person[140]	new[140]	_	_
19-4	2932-2942	biologists	person[140]	new[140]	_	_
19-5	2943-2947	also	_	_	_	_
19-6	2948-2960	increasingly	_	_	_	_
19-7	2961-2965	rely	_	_	_	_
19-8	2966-2968	on	_	_	_	_
19-9	2969-2977	directed	abstract[141]	giv[141]	coref	20-4[143_141]
19-10	2978-2987	evolution	abstract[141]	giv[141]	_	_
19-11	2988-2990	to	_	_	_	_
19-12	2991-2999	optimize	_	_	_	_
19-13	3000-3010	engineered	abstract[142]	giv[142]	_	_
19-14	3011-3021	biological	abstract[142]	giv[142]	_	_
19-15	3022-3029	systems	abstract[142]	giv[142]	_	_
19-16	3030-3031	.	_	_	_	_

#Text=However , for directed evolution to be truly effective , very large libraries of mutants must be screened under conditions that closely match the desired functionality .
20-1	3032-3039	However	_	_	_	_
20-2	3040-3041	,	_	_	_	_
20-3	3042-3045	for	_	_	_	_
20-4	3046-3054	directed	abstract[143]	giv[143]	coref	21-20[154_143]
20-5	3055-3064	evolution	abstract[143]	giv[143]	_	_
20-6	3065-3067	to	abstract[143]	giv[143]	_	_
20-7	3068-3070	be	abstract[143]	giv[143]	_	_
20-8	3071-3076	truly	abstract[143]	giv[143]	_	_
20-9	3077-3086	effective	abstract[143]	giv[143]	_	_
20-10	3087-3088	,	_	_	_	_
20-11	3089-3093	very	object[144]	giv[144]	_	_
20-12	3094-3099	large	object[144]	giv[144]	_	_
20-13	3100-3109	libraries	object[144]	giv[144]	_	_
20-14	3110-3112	of	object[144]	giv[144]	_	_
20-15	3113-3120	mutants	object[144]|quantity	giv[144]|giv	coref	21-27[156_0]
20-16	3121-3125	must	_	_	_	_
20-17	3126-3128	be	_	_	_	_
20-18	3129-3137	screened	_	_	_	_
20-19	3138-3143	under	_	_	_	_
20-20	3144-3154	conditions	abstract	giv	_	_
20-21	3155-3159	that	_	_	_	_
20-22	3160-3167	closely	_	_	_	_
20-23	3168-3173	match	_	_	_	_
20-24	3174-3177	the	abstract[147]	giv[147]	_	_
20-25	3178-3185	desired	abstract[147]	giv[147]	_	_
20-26	3186-3199	functionality	abstract[147]	giv[147]	_	_
20-27	3200-3201	.	_	_	_	_

#Text=Thus , the throughput of screening for variants with improved traits is a major factor dictating the efficiency of directed evolution given that the libraries of random mutants can be easily on the scale of 108 – 109 .
21-1	3202-3206	Thus	_	_	_	_
21-2	3207-3208	,	_	_	_	_
21-3	3209-3212	the	abstract[148]	new[148]	coref	21-13[152_148]
21-4	3213-3223	throughput	abstract[148]	new[148]	_	_
21-5	3224-3226	of	abstract[148]	new[148]	_	_
21-6	3227-3236	screening	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
21-7	3237-3240	for	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
21-8	3241-3249	variants	abstract[148]|abstract[149]|object[150]	new[148]|giv[149]|giv[150]	coref	25-23[0_150]
21-9	3250-3254	with	abstract[148]|abstract[149]|object[150]	new[148]|giv[149]|giv[150]	_	_
21-10	3255-3263	improved	abstract[148]|abstract[149]|object[150]|abstract[151]	new[148]|giv[149]|giv[150]|giv[151]	_	_
21-11	3264-3270	traits	abstract[148]|abstract[149]|object[150]|abstract[151]	new[148]|giv[149]|giv[150]|giv[151]	_	_
21-12	3271-3273	is	_	_	_	_
21-13	3274-3275	a	abstract[152]	giv[152]	_	_
21-14	3276-3281	major	abstract[152]	giv[152]	_	_
21-15	3282-3288	factor	abstract[152]	giv[152]	_	_
21-16	3289-3298	dictating	_	_	_	_
21-17	3299-3302	the	abstract[153]	new[153]	coref	26-32[203_153]
21-18	3303-3313	efficiency	abstract[153]	new[153]	_	_
21-19	3314-3316	of	abstract[153]	new[153]	_	_
21-20	3317-3325	directed	abstract[153]|abstract[154]	new[153]|giv[154]	coref	26-8[196_154]
21-21	3326-3335	evolution	abstract[153]|abstract[154]	new[153]|giv[154]	_	_
21-22	3336-3341	given	_	_	_	_
21-23	3342-3346	that	_	_	_	_
21-24	3347-3350	the	abstract[155]	new[155]	coref	23-14[171_155]
21-25	3351-3360	libraries	abstract[155]	new[155]	_	_
21-26	3361-3363	of	abstract[155]	new[155]	_	_
21-27	3364-3370	random	abstract[155]|quantity[156]	new[155]|giv[156]	coref	26-18[200_156]
21-28	3371-3378	mutants	abstract[155]|quantity[156]	new[155]|giv[156]	_	_
21-29	3379-3382	can	_	_	_	_
21-30	3383-3385	be	_	_	_	_
21-31	3386-3392	easily	abstract[157]	new[157]	_	_
21-32	3393-3395	on	abstract[157]	new[157]	_	_
21-33	3396-3399	the	abstract[157]	new[157]	_	_
21-34	3400-3405	scale	abstract[157]	new[157]	_	_
21-35	3406-3408	of	abstract[157]	new[157]	_	_
21-36	3409-3412	108	abstract[157]|quantity[158]	new[157]|new[158]	_	_
21-37	3413-3414	–	abstract[157]|quantity[158]	new[157]|new[158]	_	_
21-38	3415-3418	109	abstract[157]|quantity[158]|quantity	new[157]|new[158]|new	_	_
21-39	3419-3420	.	_	_	_	_

#Text=Proteins are engineered for properties such as affinity , selectivity , stability or enzymatic activity .
22-1	3421-3429	Proteins	object	giv	_	_
22-2	3430-3433	are	_	_	_	_
22-3	3434-3444	engineered	_	_	_	_
22-4	3445-3448	for	_	_	_	_
22-5	3449-3459	properties	abstract[161]	giv[161]	coref	28-3[219_161]
22-6	3460-3464	such	abstract[161]	giv[161]	_	_
22-7	3465-3467	as	abstract[161]	giv[161]	_	_
22-8	3468-3476	affinity	abstract[161]|abstract	giv[161]|new	_	_
22-9	3477-3478	,	abstract[161]	giv[161]	_	_
22-10	3479-3490	selectivity	abstract[161]|abstract	giv[161]|new	_	_
22-11	3491-3492	,	abstract[161]	giv[161]	_	_
22-12	3493-3502	stability	abstract[161]|abstract	giv[161]|giv	_	_
22-13	3503-3505	or	abstract[161]	giv[161]	_	_
22-14	3506-3515	enzymatic	abstract[161]|place|abstract[166]	giv[161]|new|new[166]	_	_
22-15	3516-3524	activity	abstract[161]|abstract[166]	giv[161]|new[166]	_	_
22-16	3525-3526	.	_	_	_	_

#Text=Often , when a cell based fluorescent readout is achievable , screening of engineered protein libraries is performed with fluorescence-activated cell sorting ( FACS ) to separate a population of cells into sub-populations based on fluorescent labeling .
23-1	3527-3532	Often	_	_	_	_
23-2	3533-3534	,	_	_	_	_
23-3	3535-3539	when	_	_	_	_
23-4	3540-3541	a	object[167]	new[167]	coref	23-21[0_167]
23-5	3542-3546	cell	object[167]	new[167]	_	_
23-6	3547-3552	based	_	_	_	_
23-7	3553-3564	fluorescent	abstract[168]	new[168]	_	_
23-8	3565-3572	readout	abstract[168]	new[168]	_	_
23-9	3573-3575	is	_	_	_	_
23-10	3576-3586	achievable	_	_	_	_
23-11	3587-3588	,	_	_	_	_
23-12	3589-3598	screening	abstract[169]	new[169]	coref	30-17[0_169]
23-13	3599-3601	of	abstract[169]	new[169]	_	_
23-14	3602-3612	engineered	abstract[169]|object[171]	new[169]|giv[171]	_	_
23-15	3613-3620	protein	abstract[169]|substance|object[171]	new[169]|giv|giv[171]	coref	28-30[224_0]
23-16	3621-3630	libraries	abstract[169]|object[171]	new[169]|giv[171]	_	_
23-17	3631-3633	is	_	_	_	_
23-18	3634-3643	performed	_	_	_	_
23-19	3644-3648	with	_	_	_	_
23-20	3649-3671	fluorescence-activated	abstract[173]	new[173]	appos	23-24[0_173]
23-21	3672-3676	cell	object|abstract[173]	giv|new[173]	coref	27-25[215_0]
23-22	3677-3684	sorting	abstract[173]	new[173]	_	_
23-23	3685-3686	(	_	_	_	_
23-24	3687-3691	FACS	abstract	giv	coref	25-36
23-25	3692-3693	)	_	_	_	_
23-26	3694-3696	to	_	_	_	_
23-27	3697-3705	separate	_	_	_	_
23-28	3706-3707	a	abstract[175]	new[175]	coref	27-28[217_175]
23-29	3708-3718	population	abstract[175]	new[175]	_	_
23-30	3719-3721	of	abstract[175]	new[175]	_	_
23-31	3722-3727	cells	abstract[175]|object	new[175]|new	coref	24-11[182_0]
23-32	3728-3732	into	_	_	_	_
23-33	3733-3748	sub-populations	abstract	new	ana	27-2
23-34	3749-3754	based	_	_	_	_
23-35	3755-3757	on	_	_	_	_
23-36	3758-3769	fluorescent	object[178]	new[178]	_	_
23-37	3770-3778	labeling	object[178]	new[178]	_	_
23-38	3779-3780	.	_	_	_	_

#Text=In this case , the phenotype-genotype connection is unbroken because the cells are selected directly .
24-1	3781-3783	In	_	_	_	_
24-2	3784-3788	this	event[179]	new[179]	_	_
24-3	3789-3793	case	event[179]	new[179]	_	_
24-4	3794-3795	,	_	_	_	_
24-5	3796-3799	the	abstract[181]	new[181]	_	_
24-6	3800-3818	phenotype-genotype	abstract|abstract[181]	new|new[181]	_	_
24-7	3819-3829	connection	abstract[181]	new[181]	_	_
24-8	3830-3832	is	_	_	_	_
24-9	3833-3841	unbroken	_	_	_	_
24-10	3842-3849	because	_	_	_	_
24-11	3850-3853	the	object[182]	giv[182]	coref	27-10[212_182]
24-12	3854-3859	cells	object[182]	giv[182]	_	_
24-13	3860-3863	are	_	_	_	_
24-14	3864-3872	selected	_	_	_	_
24-15	3873-3881	directly	_	_	_	_
24-16	3882-3883	.	_	_	_	_

#Text=For example , Lipovšek et al. reported in vitro selection of catalytically active enzymes ( horseradish peroxidase ) from large libraries of variants displayed on the surface of the yeast S. cerevisiae and separated by FACS .
25-1	3884-3887	For	_	_	_	_
25-2	3888-3895	example	_	_	_	_
25-3	3896-3897	,	_	_	_	_
25-4	3898-3906	Lipovšek	person	new	_	_
25-5	3907-3909	et	_	_	_	_
25-6	3910-3913	al.	_	_	_	_
25-7	3914-3922	reported	_	_	_	_
25-8	3923-3925	in	_	_	_	_
25-9	3926-3931	vitro	abstract[184]	giv[184]	coref	29-46[242_184]
25-10	3932-3941	selection	abstract[184]	giv[184]	_	_
25-11	3942-3944	of	abstract[184]	giv[184]	_	_
25-12	3945-3958	catalytically	abstract[184]|substance[185]	giv[184]|giv[185]	_	_
25-13	3959-3965	active	abstract[184]|substance[185]	giv[184]|giv[185]	_	_
25-14	3966-3973	enzymes	abstract[184]|substance[185]	giv[184]|giv[185]	_	_
25-15	3974-3975	(	_	_	_	_
25-16	3976-3987	horseradish	object|object[187]	new|new[187]	_	_
25-17	3988-3998	peroxidase	object[187]	new[187]	_	_
25-18	3999-4000	)	_	_	_	_
25-19	4001-4005	from	_	_	_	_
25-20	4006-4011	large	place[188]	new[188]	_	_
25-21	4012-4021	libraries	place[188]	new[188]	_	_
25-22	4022-4024	of	place[188]	new[188]	_	_
25-23	4025-4033	variants	place[188]|object	new[188]|giv	_	_
25-24	4034-4043	displayed	_	_	_	_
25-25	4044-4046	on	_	_	_	_
25-26	4047-4050	the	place[190]	new[190]	_	_
25-27	4051-4058	surface	place[190]	new[190]	_	_
25-28	4059-4061	of	place[190]	new[190]	_	_
25-29	4062-4065	the	place[190]|animal[191]	new[190]|new[191]	_	_
25-30	4066-4071	yeast	place[190]|animal[191]	new[190]|new[191]	_	_
25-31	4072-4074	S.	_	_	_	_
25-32	4075-4085	cerevisiae	_	_	_	_
25-33	4086-4089	and	_	_	_	_
25-34	4090-4099	separated	_	_	_	_
25-35	4100-4102	by	_	_	_	_
25-36	4103-4107	FACS	object	giv	coref	26-24
25-37	4108-4109	.	_	_	_	_

#Text=To improve substrate specificity of glycosyltransferases by directed evolution , Aharoni et al. screened a library of over a million sialyltransferases mutants using FACS and found a variant with up to 400-fold higher catalytic efficiency for transfer to a variety of fluorescently labeled acceptor sugars .
26-1	4110-4112	To	_	_	_	_
26-2	4113-4120	improve	_	_	_	_
26-3	4121-4130	substrate	person|abstract[194]	new|new[194]	_	_
26-4	4131-4142	specificity	abstract[194]	new[194]	_	_
26-5	4143-4145	of	abstract[194]	new[194]	_	_
26-6	4146-4166	glycosyltransferases	abstract[194]|substance[195]	new[194]|new[195]	_	_
26-7	4167-4169	by	abstract[194]|substance[195]	new[194]|new[195]	_	_
26-8	4170-4178	directed	abstract[194]|substance[195]|abstract[196]	new[194]|new[195]|giv[196]	_	_
26-9	4179-4188	evolution	abstract[194]|substance[195]|abstract[196]	new[194]|new[195]|giv[196]	_	_
26-10	4189-4190	,	abstract[194]|substance[195]	new[194]|new[195]	_	_
26-11	4191-4198	Aharoni	abstract[194]|substance[195]|person	new[194]|new[195]|new	_	_
26-12	4199-4201	et	abstract[194]|substance[195]	new[194]|new[195]	_	_
26-13	4202-4205	al.	abstract[194]|substance[195]	new[194]|new[195]	_	_
26-14	4206-4214	screened	_	_	_	_
26-15	4215-4216	a	organization[198]	new[198]	_	_
26-16	4217-4224	library	organization[198]	new[198]	_	_
26-17	4225-4227	of	organization[198]	new[198]	_	_
26-18	4228-4232	over	organization[198]|quantity[200]	new[198]|giv[200]	_	_
26-19	4233-4234	a	organization[198]|quantity[200]	new[198]|giv[200]	_	_
26-20	4235-4242	million	organization[198]|quantity[200]	new[198]|giv[200]	_	_
26-21	4243-4261	sialyltransferases	organization[198]|object|quantity[200]	new[198]|new|giv[200]	_	_
26-22	4262-4269	mutants	organization[198]|quantity[200]	new[198]|giv[200]	_	_
26-23	4270-4275	using	_	_	_	_
26-24	4276-4280	FACS	object	giv	coref	27-37
26-25	4281-4284	and	_	_	_	_
26-26	4285-4290	found	_	_	_	_
26-27	4291-4292	a	object[202]	giv[202]	_	_
26-28	4293-4300	variant	object[202]	giv[202]	_	_
26-29	4301-4305	with	object[202]	giv[202]	_	_
26-30	4306-4308	up	object[202]	giv[202]	_	_
26-31	4309-4311	to	object[202]	giv[202]	_	_
26-32	4312-4320	400-fold	object[202]|abstract[203]	giv[202]|giv[203]	_	_
26-33	4321-4327	higher	object[202]|abstract[203]	giv[202]|giv[203]	_	_
26-34	4328-4337	catalytic	object[202]|abstract[203]	giv[202]|giv[203]	_	_
26-35	4338-4348	efficiency	object[202]|abstract[203]	giv[202]|giv[203]	_	_
26-36	4349-4352	for	object[202]|abstract[203]	giv[202]|giv[203]	_	_
26-37	4353-4361	transfer	object[202]|abstract[203]|abstract[204]	giv[202]|giv[203]|new[204]	coref	27-22[0_204]
26-38	4362-4364	to	object[202]|abstract[203]|abstract[204]	giv[202]|giv[203]|new[204]	_	_
26-39	4365-4366	a	object[202]|abstract[203]|abstract[204]|abstract[205]	giv[202]|giv[203]|new[204]|new[205]	_	_
26-40	4367-4374	variety	object[202]|abstract[203]|abstract[204]|abstract[205]	giv[202]|giv[203]|new[204]|new[205]	_	_
26-41	4375-4377	of	object[202]|abstract[203]|abstract[204]|abstract[205]	giv[202]|giv[203]|new[204]|new[205]	_	_
26-42	4378-4391	fluorescently	object[202]|abstract[203]|abstract[204]|abstract[205]|substance[207]	giv[202]|giv[203]|new[204]|new[205]|new[207]	_	_
26-43	4392-4399	labeled	object[202]|abstract[203]|abstract[204]|abstract[205]|substance[207]	giv[202]|giv[203]|new[204]|new[205]|new[207]	_	_
26-44	4400-4408	acceptor	object[202]|abstract[203]|abstract[204]|abstract[205]|person|substance[207]	giv[202]|giv[203]|new[204]|new[205]|new|new[207]	_	_
26-45	4409-4415	sugars	object[202]|abstract[203]|abstract[204]|abstract[205]|substance[207]	giv[202]|giv[203]|new[204]|new[205]|new[207]	_	_
26-46	4416-4417	.	_	_	_	_

#Text=In their study , the formation of sialosides in intact E. coli cells was detected by selectively trapping the fluorescently labeled transfer products within the cell and the resulting cell population was analyzed and sorted using FACS .
27-1	4418-4420	In	_	_	_	_
27-2	4421-4426	their	abstract|abstract[209]	giv|new[209]	_	_
27-3	4427-4432	study	abstract[209]	new[209]	_	_
27-4	4433-4434	,	_	_	_	_
27-5	4435-4438	the	abstract[210]	new[210]	_	_
27-6	4439-4448	formation	abstract[210]	new[210]	_	_
27-7	4449-4451	of	abstract[210]	new[210]	_	_
27-8	4452-4462	sialosides	abstract[210]|substance	new[210]|new	_	_
27-9	4463-4465	in	abstract[210]	new[210]	_	_
27-10	4466-4472	intact	abstract[210]|object[212]	new[210]|giv[212]	coref	29-31[237_212]
27-11	4473-4475	E.	abstract[210]|object[212]	new[210]|giv[212]	_	_
27-12	4476-4480	coli	abstract[210]|object[212]	new[210]|giv[212]	_	_
27-13	4481-4486	cells	abstract[210]|object[212]	new[210]|giv[212]	_	_
27-14	4487-4490	was	_	_	_	_
27-15	4491-4499	detected	_	_	_	_
27-16	4500-4502	by	_	_	_	_
27-17	4503-4514	selectively	_	_	_	_
27-18	4515-4523	trapping	_	_	_	_
27-19	4524-4527	the	object[214]	new[214]	_	_
27-20	4528-4541	fluorescently	object[214]	new[214]	_	_
27-21	4542-4549	labeled	object[214]	new[214]	_	_
27-22	4550-4558	transfer	abstract|object[214]	giv|new[214]	_	_
27-23	4559-4567	products	object[214]	new[214]	_	_
27-24	4568-4574	within	object[214]	new[214]	_	_
27-25	4575-4578	the	object[214]|object[215]	new[214]|giv[215]	coref	27-30[0_215]
27-26	4579-4583	cell	object[214]|object[215]	new[214]|giv[215]	_	_
27-27	4584-4587	and	_	_	_	_
27-28	4588-4591	the	abstract[217]	giv[217]	_	_
27-29	4592-4601	resulting	abstract[217]	giv[217]	_	_
27-30	4602-4606	cell	object|abstract[217]	giv|giv[217]	coref	28-21[223_0]
27-31	4607-4617	population	abstract[217]	giv[217]	_	_
27-32	4618-4621	was	_	_	_	_
27-33	4622-4630	analyzed	_	_	_	_
27-34	4631-4634	and	_	_	_	_
27-35	4635-4641	sorted	_	_	_	_
27-36	4642-4647	using	_	_	_	_
27-37	4648-4652	FACS	object	giv	coref	28-13
27-38	4653-4654	.	_	_	_	_

#Text=However , many desirable properties are not amenable to direct interrogation via FACS because the phenotype is not inherent in a single cell , for example , when improving a protein excreted into growth medium .
28-1	4655-4662	However	_	_	_	_
28-2	4663-4664	,	_	_	_	_
28-3	4665-4669	many	abstract[219]	giv[219]	coref	29-1[227_219]
28-4	4670-4679	desirable	abstract[219]	giv[219]	_	_
28-5	4680-4690	properties	abstract[219]	giv[219]	_	_
28-6	4691-4694	are	_	_	_	_
28-7	4695-4698	not	_	_	_	_
28-8	4699-4707	amenable	_	_	_	_
28-9	4708-4710	to	_	_	_	_
28-10	4711-4717	direct	_	_	_	_
28-11	4718-4731	interrogation	abstract[220]	new[220]	_	_
28-12	4732-4735	via	abstract[220]	new[220]	_	_
28-13	4736-4740	FACS	abstract[220]|abstract	new[220]|giv	_	_
28-14	4741-4748	because	_	_	_	_
28-15	4749-4752	the	abstract[222]	new[222]	coref	29-43[241_222]
28-16	4753-4762	phenotype	abstract[222]	new[222]	_	_
28-17	4763-4765	is	_	_	_	_
28-18	4766-4769	not	_	_	_	_
28-19	4770-4778	inherent	_	_	_	_
28-20	4779-4781	in	_	_	_	_
28-21	4782-4783	a	object[223]	giv[223]	_	_
28-22	4784-4790	single	object[223]	giv[223]	_	_
28-23	4791-4795	cell	object[223]	giv[223]	_	_
28-24	4796-4797	,	_	_	_	_
28-25	4798-4801	for	_	_	_	_
28-26	4802-4809	example	_	_	_	_
28-27	4810-4811	,	_	_	_	_
28-28	4812-4816	when	_	_	_	_
28-29	4817-4826	improving	_	_	_	_
28-30	4827-4828	a	substance[224]	giv[224]	_	_
28-31	4829-4836	protein	substance[224]	giv[224]	_	_
28-32	4837-4845	excreted	_	_	_	_
28-33	4846-4850	into	_	_	_	_
28-34	4851-4857	growth	abstract|substance[226]	new|new[226]	_	_
28-35	4858-4864	medium	substance[226]	new[226]	_	_
28-36	4865-4866	.	_	_	_	_

#Text=Properties such as extracellular analyte consumption , product secretion and cell-cell interactions are not readily detectable with flow cytometry . Screening for ‘ non-cellular ’ phenotypes necessitates the compartmentalization of single cells or an alternative expression system to maintain the linkage between the phenotype that the selection acts on and the genotype in which the evolutionary information is encoded .
29-1	4867-4877	Properties	abstract[227]	giv[227]	_	_
29-2	4878-4882	such	abstract[227]	giv[227]	_	_
29-3	4883-4885	as	abstract[227]	giv[227]	_	_
29-4	4886-4899	extracellular	abstract[227]|abstract[229]	giv[227]|new[229]	_	_
29-5	4900-4907	analyte	abstract[227]|abstract|abstract[229]	giv[227]|new|new[229]	_	_
29-6	4908-4919	consumption	abstract[227]|abstract[229]	giv[227]|new[229]	_	_
29-7	4920-4921	,	abstract[227]	giv[227]	_	_
29-8	4922-4929	product	abstract[227]|abstract|substance[231]	giv[227]|new|new[231]	_	_
29-9	4930-4939	secretion	abstract[227]|substance[231]	giv[227]|new[231]	_	_
29-10	4940-4943	and	abstract[227]	giv[227]	_	_
29-11	4944-4953	cell-cell	abstract[227]|abstract[232]	giv[227]|new[232]	_	_
29-12	4954-4966	interactions	abstract[227]|abstract[232]	giv[227]|new[232]	_	_
29-13	4967-4970	are	_	_	_	_
29-14	4971-4974	not	_	_	_	_
29-15	4975-4982	readily	_	_	_	_
29-16	4983-4993	detectable	_	_	_	_
29-17	4994-4998	with	_	_	_	_
29-18	4999-5003	flow	abstract|abstract[234]	new|new[234]	_	_
29-19	5004-5013	cytometry	abstract[234]	new[234]	_	_
29-20	5014-5015	.	_	_	_	_
29-21	5016-5025	Screening	_	_	_	_
29-22	5026-5029	for	_	_	_	_
29-23	5030-5031	‘	abstract[235]	new[235]	_	_
29-24	5032-5044	non-cellular	abstract[235]	new[235]	_	_
29-25	5045-5046	’	abstract[235]	new[235]	_	_
29-26	5047-5057	phenotypes	abstract[235]	new[235]	_	_
29-27	5058-5070	necessitates	_	_	_	_
29-28	5071-5074	the	abstract[236]	new[236]	_	_
29-29	5075-5095	compartmentalization	abstract[236]	new[236]	_	_
29-30	5096-5098	of	abstract[236]	new[236]	_	_
29-31	5099-5105	single	abstract[236]|object[237]	new[236]|giv[237]	_	_
29-32	5106-5111	cells	abstract[236]|object[237]	new[236]|giv[237]	_	_
29-33	5112-5114	or	abstract[236]|object[237]	new[236]|giv[237]	_	_
29-34	5115-5117	an	abstract[236]|object[237]|abstract[239]	new[236]|giv[237]|new[239]	_	_
29-35	5118-5129	alternative	abstract[236]|object[237]|abstract[239]	new[236]|giv[237]|new[239]	_	_
29-36	5130-5140	expression	abstract[236]|object[237]|abstract|abstract[239]	new[236]|giv[237]|new|new[239]	_	_
29-37	5141-5147	system	abstract[236]|object[237]|abstract[239]	new[236]|giv[237]|new[239]	_	_
29-38	5148-5150	to	_	_	_	_
29-39	5151-5159	maintain	_	_	_	_
29-40	5160-5163	the	abstract[240]	new[240]	_	_
29-41	5164-5171	linkage	abstract[240]	new[240]	_	_
29-42	5172-5179	between	abstract[240]	new[240]	_	_
29-43	5180-5183	the	abstract[240]|abstract[241]	new[240]|giv[241]	_	_
29-44	5184-5193	phenotype	abstract[240]|abstract[241]	new[240]|giv[241]	_	_
29-45	5194-5198	that	_	_	_	_
29-46	5199-5202	the	abstract[242]	giv[242]	_	_
29-47	5203-5212	selection	abstract[242]	giv[242]	_	_
29-48	5213-5217	acts	_	_	_	_
29-49	5218-5220	on	_	_	_	_
29-50	5221-5224	and	_	_	_	_
29-51	5225-5228	the	abstract[243]	new[243]	_	_
29-52	5229-5237	genotype	abstract[243]	new[243]	_	_
29-53	5238-5240	in	_	_	_	_
29-54	5241-5246	which	_	_	_	_
29-55	5247-5250	the	abstract[244]	giv[244]	_	_
29-56	5251-5263	evolutionary	abstract[244]	giv[244]	_	_
29-57	5264-5275	information	abstract[244]	giv[244]	_	_
29-58	5276-5278	is	_	_	_	_
29-59	5279-5286	encoded	_	_	_	_
29-60	5287-5288	.	_	_	_	_

#Text=Compartmentalization of assays in arrays of wells makes microtiter plates by far the most widely used screening platform .
30-1	5289-5309	Compartmentalization	abstract[245]	new[245]	_	_
30-2	5310-5312	of	abstract[245]	new[245]	_	_
30-3	5313-5319	assays	abstract[245]|place	new[245]|new	_	_
30-4	5320-5322	in	abstract[245]	new[245]	_	_
30-5	5323-5329	arrays	abstract[245]|place[247]	new[245]|new[247]	_	_
30-6	5330-5332	of	abstract[245]|place[247]	new[245]|new[247]	_	_
30-7	5333-5338	wells	abstract[245]|place[247]|person	new[245]|new[247]|new	_	_
30-8	5339-5344	makes	_	_	_	_
30-9	5345-5355	microtiter	object[249]	new[249]	coref	32-9[261_249]
30-10	5356-5362	plates	object[249]	new[249]	_	_
30-11	5363-5365	by	object[249]	new[249]	_	_
30-12	5366-5369	far	object[249]|abstract[251]	new[249]|new[251]	_	_
30-13	5370-5373	the	object[249]|abstract[251]	new[249]|new[251]	_	_
30-14	5374-5378	most	object[249]|abstract[251]	new[249]|new[251]	_	_
30-15	5379-5385	widely	object[249]|abstract[251]	new[249]|new[251]	_	_
30-16	5386-5390	used	object[249]|abstract[251]	new[249]|new[251]	_	_
30-17	5391-5400	screening	object[249]|abstract|abstract[251]	new[249]|giv|new[251]	_	_
30-18	5401-5409	platform	object[249]|abstract[251]	new[249]|new[251]	_	_
30-19	5410-5411	.	_	_	_	_

#Text=However , the microplate-based method becomes problematic when the assay volume is less than 1 µL due to evaporation and capillary forces .
31-1	5412-5419	However	_	_	_	_
31-2	5420-5421	,	_	_	_	_
31-3	5422-5425	the	abstract[252]	new[252]	_	_
31-4	5426-5442	microplate-based	abstract[252]	new[252]	_	_
31-5	5443-5449	method	abstract[252]	new[252]	_	_
31-6	5450-5457	becomes	_	_	_	_
31-7	5458-5469	problematic	_	_	_	_
31-8	5470-5474	when	_	_	_	_
31-9	5475-5478	the	quantity[254]	new[254]	coref	31-13[255_254]
31-10	5479-5484	assay	object|quantity[254]	new|new[254]	coref	32-25[266_0]
31-11	5485-5491	volume	quantity[254]	new[254]	_	_
31-12	5492-5494	is	_	_	_	_
31-13	5495-5499	less	quantity[255]	giv[255]	_	_
31-14	5500-5504	than	quantity[255]	giv[255]	_	_
31-15	5505-5506	1	quantity[255]	giv[255]	_	_
31-16	5507-5509	µL	quantity[255]	giv[255]	_	_
31-17	5510-5513	due	quantity[255]	giv[255]	_	_
31-18	5514-5516	to	_	_	_	_
31-19	5517-5528	evaporation	abstract	new	_	_
31-20	5529-5532	and	_	_	_	_
31-21	5533-5542	capillary	abstract|abstract[258]	new|new[258]	_	_
31-22	5543-5549	forces	abstract[258]	new[258]	_	_
31-23	5550-5551	.	_	_	_	_

#Text=Even with robotic automation for liquid handling using 1536-well plates and assuming a processing rate of 1 plate per minute , the throughput of a well based assay is approximately 25 samples/sec for a prompt optical measurement .
32-1	5552-5556	Even	event[259]	new[259]	_	_
32-2	5557-5561	with	event[259]	new[259]	_	_
32-3	5562-5569	robotic	event[259]	new[259]	_	_
32-4	5570-5580	automation	event[259]	new[259]	_	_
32-5	5581-5584	for	event[259]	new[259]	_	_
32-6	5585-5591	liquid	event[259]|substance	new[259]|new	_	_
32-7	5592-5600	handling	_	_	_	_
32-8	5601-5606	using	_	_	_	_
32-9	5607-5616	1536-well	object[261]	giv[261]	_	_
32-10	5617-5623	plates	object[261]	giv[261]	_	_
32-11	5624-5627	and	_	_	_	_
32-12	5628-5636	assuming	_	_	_	_
32-13	5637-5638	a	abstract[262]	new[262]	_	_
32-14	5639-5649	processing	abstract[262]	new[262]	_	_
32-15	5650-5654	rate	abstract[262]	new[262]	_	_
32-16	5655-5657	of	abstract[262]	new[262]	_	_
32-17	5658-5659	1	abstract[262]|time[263]	new[262]|new[263]	_	_
32-18	5660-5665	plate	abstract[262]|time[263]	new[262]|new[263]	_	_
32-19	5666-5669	per	abstract[262]|time[263]	new[262]|new[263]	_	_
32-20	5670-5676	minute	abstract[262]|time[263]|time	new[262]|new[263]|new	_	_
32-21	5677-5678	,	_	_	_	_
32-22	5679-5682	the	quantity[265]	new[265]	coref	32-30[267_265]
32-23	5683-5693	throughput	quantity[265]	new[265]	_	_
32-24	5694-5696	of	quantity[265]	new[265]	_	_
32-25	5697-5698	a	quantity[265]|object[266]	new[265]|giv[266]	_	_
32-26	5699-5703	well	quantity[265]|object[266]	new[265]|giv[266]	_	_
32-27	5704-5709	based	quantity[265]|object[266]	new[265]|giv[266]	_	_
32-28	5710-5715	assay	quantity[265]|object[266]	new[265]|giv[266]	_	_
32-29	5716-5718	is	_	_	_	_
32-30	5719-5732	approximately	quantity[267]	giv[267]	_	_
32-31	5733-5735	25	quantity[267]	giv[267]	_	_
32-32	5736-5747	samples/sec	quantity[267]	giv[267]	_	_
32-33	5748-5751	for	quantity[267]	giv[267]	_	_
32-34	5752-5753	a	quantity[267]|event[268]	giv[267]|new[268]	_	_
32-35	5754-5760	prompt	quantity[267]|event[268]	giv[267]|new[268]	_	_
32-36	5761-5768	optical	quantity[267]|event[268]	giv[267]|new[268]	_	_
32-37	5769-5780	measurement	quantity[267]|event[268]	giv[267]|new[268]	_	_
32-38	5781-5782	.	_	_	_	_
